Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Goldman Sachs says stick with Asia's winners, keep diversifying into commodities
The bank retained an overweight recommendation on North Asia, favouring South Korea, Taiwan, Japan and China's domestic A-share market, alongside technology hardware, capital goods and banks.
Zerodha plans entry into investment banking space with SEBI licence application: Report
Zerodha seeks SEBI Category I merchant banking licence, aiming to manage IPOs and expand corporate finance services amid India's booming capital markets.
Persistent Systems: Nagarro Deal Positive, but Dolat Capital Remains Bearish — Check Target Price
Persistent Systems shares are likely to be in focus after Dolat Capital maintained a Sell', citing premium valuations, near-term earnings pressure, and execution risks linked to its acquisition of Nagarro.
Rupee opens 5 paise higher at 94.35 against US dollar
The Indian rupee strengthened to 94.35 against the US dollar, supported by lower oil prices despite potential global risks. Analysts suggest the rupee may trade within the 94-95 range, with strong capital inflows providing some buffer against a firm US dollar.
HDFC Bank likely to reappoint Sashidhar Jagdishan as CEO for third term
HDFC Bank's board is poised to reappoint Sashidhar Jagdishan as MD & CEO for a third term following external legal reviews clearing the bank of concerns raised by a former chairman. While the board and Macquarie Capital support Jagdishan, the RBI's approval remains crucial, with analysts noting the regulator may consider broader factors. The bank's elevated loan-to-deposit ratio, a post-merger challenge, is also a point of consideration.
Incuspaze raises Rs 150 crore to fuel expansion ahead of FY29 IPO
Flexible workspace provider Incuspaze has secured Rs 150 crore in a significant funding round led by Bharat Value Fund. This capital injection will fuel expansion in key markets, boost technology investments, and support acquisitions as the company eyes a public listing in FY29. The funding follows Incuspaze's recent acquisition of iKeva, bolstering its presence in Hyderabad and its overall growth strategy.
Baring Private Equity India, Anchorage Capital Fund among 5 investors pick up Rs 100 crore Caliber Mining... - Moneycontrol.com
Baring Private Equity India, Anchorage Capital Fund among 5 investors pick up Rs 100 crore Caliber Mining...Moneycontrol.com
Tax, policy changes making equities more attractive for investors, likely to sustain inflows: JP Morgan
Government policies and tax reforms are making Indian equities a more attractive investment compared to other options, according to a JP Morgan report. These changes, coupled with rising investor participation via Systematic Investment Plans (SIPs), are expected to drive sustained inflows into the country's capital markets. Domestic investors are increasingly shifting savings towards financial assets, a trend reinforced by the favourable policy environment.
The hidden reason global capital is looking beyond India for future growth - The Economic Times
The hidden reason global capital is looking beyond India for future growthThe Economic Times
The hidden reason global capital is looking beyond India for future growth
Foreign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI and semiconductor growth. The trend highlights India’s structural gaps in innovation, limited deep-tech opportunities in listed markets, and rising concerns over valuations amid moderating earnings and slowing capital inflows.
Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore
Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.
Strides Pharma to monetise stake in Pivot Path; company valued at ₹230 crore post-money
Strides Pharma Science Limited will monetise its stake in subsidiary Pivot Path Private Limited in a transaction led by Ascent Capital, alongside co-investor Vintage Classic, valuing the entity at near ₹230 crore post-money. The company will realise near ₹100 crore while retaining near 20% ownership and also receive a primary capital infusion of ₹50 crore into the business.